Date post: | 14-Jul-2015 |
Category: |
Presentations & Public Speaking |
Upload: | laboratoridalbasso |
View: | 93 times |
Download: | 3 times |
TTFactor @ Laboratori dal Basso
Jacopo Franchini, Business Development Manager TTFactor S.r.l.
Laboratori dal Basso “Geni Mutanti” Campus Ecotkne - Lecce
7 November 2014
“Dalla Ricerca al prodotto, dal prodotto al Mercato”
TTFactor @ Laboratori dal Basso
1. Doing Technology Transfer for 3 research center in Milano -‐ IEO -‐ IFOM -‐ Monzino
2. Why should industry and academia collaborate? 3. TTFactor in this context : A Tech Transfer Company 4. Career development session
INDEX
TTFactor @ Laboratori dal Basso
• European InsLtute of Oncology (IEO)
• FIRC InsLtute of Molecular Oncology (IFOM)
• Centro Cardiologico Monzino
1. Doing Technology Transfer for..
TTFactor @ Laboratori dal Basso
• Founded in 1994, as a Comprehensive Cancer Center • Private company owned by the major Italian Banks and Insurances,
part of the Na>onal Health System (IRCSS)
The Main Actors (1) • The European Ins>tute of Oncology
• Clinical Cancer Center • Research Laboratories
TTFactor @ Laboratori dal Basso
• Founded in 1999, as a Reaseach InsLtute focused on Basic Cancer Research
• Founda>on, owned by FIRC, the largest cancer-‐research Italian charity
The Main Actors (2) • The FIRC Ins>tute of Molecular Oncology
TTFactor @ Laboratori dal Basso
The Main Actors (3) • The Campus IFOM-‐IEO
Together, Ifom and Ieo, Founded the campus to expand, integrate their research acBviBes and to exploit the resultant synergies:
Ø Virtual ins>tu>on; Common Facili>es (imaging, proteomic, genomic etc.) scien>fic governance entrusted to the Scien>fic Directors of IEO and IFOM; common policies.
TTFactor @ Laboratori dal Basso
• Part of IEO’s group Founded in 1981 and IRCCS since 1992 • Private Hospital owned by IEO and part of the Na>onal Health System
(IRCSS)
• THE ONLY RESEARCH HOSPITAL IN EUROPE EXCLUSIVELY DEVOTED TO THE TREATMENT OF CARDIOVASCULAR
DISEASES
• 1ST RANKED FOR CARDIO-‐VASCULAR SURGERY RESULTS BY THE ITALIAN MINISTRY OF HEALTH
• MAJOR TRANSLATIONAL RESEARCH PROGRAMS AT CCM:
1. BIOLOGY AND BIOCHEMISTRY OF ATHEROTHROMBOSIS
2. VASCULAR BIOLOGY AND REGENERATIVE MEDICINE
3. IMMUNOLOGY AND FUNCTIONAL GENOMICS OF THE PLAQUE
4. CARDIOVASCULAR TISSUE ENGINEERING
…. And Centro Cardiologico Monzino
TTFactor @ Bocconi
The IEO Clinical Center 1400 Clinics
The IFOM-‐IEO Campus 450 Researchers 40 Research Groups 130 PhD Students (SEMM) 150 Post-‐Docs 50 Scien>sts/Technicians (Scien>fic Groups) 80 Scien>sts/Technicians (Cogentech)
Centro Cardiologico Monzino 644 Clinics 60 Research
The Main actors (4): People involved
TTFactor @ Bocconi
The IFOM-‐IEO Campus To adopt an approach driven by scienLfic curiosity and strongly based on fundamental biology
The IEO Clinical Center To provide the academic home and integrated resources to advance clinical science
• To favor and accelerate transfer of knowledge for cancer preven>on and treatment
• To build on the value of scien>fic research with a strictly non-‐profit research
Vision
TTFactor @ Laboratori dal Basso
Main drivers: • To increase R&D produc0vity; • To share the development costs/risks with a commercial
partner; • To advance clinical science for pa3ent benefit; • To find new medical solu3ons based on scien3fic results;
2) Why should industry and academia collaborate?
TTFactor @ Laboratori dal Basso
Discovery
Phase I
FDA Review/ Approval
Additional post-marketing tests
Phase III
Phase II
Preclinical Tests
Target Discovery Target Validation (2-10 Years)
Test in lab and animal models
20-80 patients; safety and Max Tollerated Dose (MTD)
100-300 patients: efficacy and side effects
1000-1500 patients: adverse events; overall survival
MARKET LAUNCH
The Long journey from R&D to the Market
TTFactor @ Laboratori dal Basso
Stage
Discovery
Pre-‐clinical
Clinical
Fda/ Emea Marke>ng Approval
Time
2-‐10 yrs
2-‐3 yrs
4-‐6 yrs
1-‐2 yrs
Compound Success Rate
10,000
250
10
1
Total Time: 12 years Total investment: 800-‐900 Mln Euro 20 years patent life -‐ Time2Mkt = Short Exclusivity
Drug Development: it is a long process
TTFactor @ Laboratori dal Basso
Success rates from first-‐in-‐man to registra>on [Data from the ten biggest drug companies 1991–2000]
Less than 1 in 50 early drug discovery projects end with a drug in the market
• DISCOVERY: cumula>ve aari>on is ~ 80%; ~ 1 in 5 projects gets as far as selec>ng a compound for clinical trials
• DEVELOPMENT: aari>on between selec>ng a compound and marke>ng is ~ 90%; ~ 1 in 10 projects reach the market
High akriLon rate and risk of failure
TTFactor @ Laboratori dal Basso
• ñRegulatory requirements – (efficacy and safety) • Targe>ng (profitable) indica>ons: rare disease or chronic • Restric>on in reimbursement by na>onal healthcare authori>es • Too much manager and few science (CEOs with no scien>fic background)
• Pressures for fast returns by shareholders • Conformism (benchmarking mania on targets and technology) • Merger mania (during past five years, top ten pharma have eliminated more than 200,000 jobs)
• The end of Blockbuster era / focus on rare disease (one shot treatment at higher price)
Industry R&D spending is growing vs low producLvity and lack of innovaLon
TTFactor @ Laboratori dal Basso
• Lack of understanding of complex disease biology
• Lack of accurate and efficient methods for target idenLficaLon/validaLon
• Lack of “conLnous validaLon process” of the targets (Basic research and following target’s valida>on ojen not closely connected)
• Lack of accurate and efficient methods for paLent straLficaLon
This is why science is key!!!
Boklenecks in drug discovery/development:
TTFactor @ Laboratori dal Basso
“…erosion in confidence in the industry and its products … …may be moving closer to a pharmaceutical ‘ice age’ and the potential extinction of the industry, at least as it exists today…”
“…Wall Street and consultants argue that shareholders will be best served by Big Pharma ending all early-stage drug research entirely.. due to limits on their internal capacity to innovate ……to license in new compounds from smaller biotech-style companies, or from academia…“
report from analysts at Morgan Stanley-Financial Times Feb 1,2010
Nature Rev. Drug Discov. 9, 203 (2010)
• Industry R&D spending is growing vs low producLvity and lack of innovaLon • The socio-‐economic demand and high failures rate are forcing pharma industry to
reassess R&D strategies to improve efficiency and producLvity • The pharmaceuLcal industry is currently embracing unprecedented levels of
change
The result? An high need for collaboraLon
TTFactor @ Laboratori dal Basso
• Reduc>on of public funds for research • Absence of specific funds dedicated to pre-‐clinical and clinical development (TRANSLATIONAL RESEARCH)
• GlobalizaLon of the compeLLon for na>onal & interna>onal resources
• Emergence of new scienLfic paradigm (biotechnologies)vs the conven>onal pharma R&D (chemistry)
Partnership with Pharma: key driver for the Academia and vice versa
TTFactor @ Laboratori dal Basso
• Licensing revenues • Start-‐up crea>on
GeneraLng new funding sources
TTFactor @ Laboratori dal Basso
• Favor translaLonal research (absence of specific funds dedicated to pre-‐clinical and clinical development)
• Be akracLve for pa>ents by offering innova>ve therapeu>c solu>ons (trial of new drugs)
Compete at the global level
TTFactor @ Laboratori dal Basso
HIV Treatment: EMTRIVA 1990: first patent filed by Emory University, Atlanta 1996: licensed to Triangle pharmaceu>cals 2003: approved by FDA and commercialized by Gilead Sciences
Cancer (glioma): Temodal®,Temozolomide 1980s: developed by Cancer Research UK 1990s: licensed to Schering-‐Plough. 2007: approved by NICE for brain tumors
MulLple Sclerosis: COPAXONE 1971: first Patent filed by Yeda (TTCompany Weizmann Ins>tute Israel). 1987: licensed to Teva PharmaceuLcals Ltd. 1996: approved by FDA
From Academia to Market
TTFactor @ Laboratori dal Basso
NASDAQ Biotechnology Index (^NBI) -‐ NASDAQ -‐ DOW-‐JONES
The Biotech Market
TTFactor @ Laboratori dal Basso
Jazz Pharmaceu>cals buys the Italian rare-‐disease drug developer Gen>um for 1 Billion USD
Intercept shares at Nasdaq has rocketed from 70 to 450 dollars in a single day (10 January)
250 Mln €
Okairos is developing the first Ebola vaccine
Biotech in Italy: a great opportunity
Tra le 15 biotech piu promeaen> (Fierce Biotech) Esempio virtuoso di
tech transfer salen>no (2006)
TTFactor @ Laboratori dal Basso
The “Death Valley”
Industry
Academia
Difficult to build a “safe road” from research to market
TTFactor @ Laboratori dal Basso
Academic Research Centers
Pharma Biotech
Academic Hospitals
Target Iden>fica>on Drug Discovery, Development, Market
Clinical Development
The LIMIT: disease mechanisms’ knowledge is limited at the academic stage
The current model: a segmented process
TTFactor @ Laboratori dal Basso
Provides the Know-‐how on drug development
Pharmas and
Biotechs
Provides the Know-‐how on disease-‐mechanisms
Academic Research Centers Provides the scien>fic
and clinical ra>onale for the drug
Hospitals
The advantage: disease mechanisms’ knowledge pervades the en>re process, interac>on is a key for success
Provides rules for protec>on of pa>ents Local
Governments
The ideal model: integraLon to create value
TTFactor @ Laboratori dal Basso
Which are the challenges?
Ø What is changing? From the sole figure of the business angel inclined to fund early stage
projects, new financial tools are emerging: • increasing presence of Corporate Venture Capital (i.e. Novar>s, J&J, Roche,
Bayer)
• Seed investments funds directly owned by universi>es’ technology transfer offices ( Imperial Innova>ons, Karolinska Investment FUND I, Momentum Fund Tel Aviv University …)
• Open innovaLon models to foster the innova>ve performance of the big
corporates ( GSK DPAC -‐ BAYER -‐ NOVARTIS BioCamp -‐ J&J Innova>on)
TTFactor @ Laboratori dal Basso
• Achieve a change in the researchers’ culture and approach to science: aiming also to reach pa>ents through applied research
• Thinking long term (tech transfer return in 5-‐10 year)
• Working together (management/scien>sts/clinicians each focusing on its task) to reach common objec>ves
• Addressing complexity earlier: collabora>ons with Universi>es and Professor affilia>ons (i.e. we have agreement Universita di Milano, Is>tuto Italiano di Tecnologia, Universita’ di Pisa, Universita’ di Pavia…)
Which are the challenges?
TTFactor @ Laboratori dal Basso
TTOFFICE
ADMINISTRATION • low costs • revenues • control/burocracy
RESEARCHERS • services • patents • publica>ons
DEAN OF RESEARCH • services • freedom of research • poli>cs
COMPANIES AND VC • efficiency • speed • authority
Why TT offices are (parLally) ineffecLve
TTFactor @ Laboratori dal Basso
A new vision of the Technology Transfer to allow the integraLon
BASIC MODEL: – Technology Transfer (“Tech Transfer 1.0”) “The IFOM-‐IEO MODEL”: – Technology Development (“Tech Transfer 2.0”)
TTFactor @ Laboratori dal Basso
TTCOMPANY
SHAREHOLDERS -‐President -‐Board of Directors
MISSION OBJECTIVES GOALS
COMPANIES AND VCs -‐efficiency -‐speed -‐authority
The importance of being a company
TTFactor @ Laboratori dal Basso
Biotech/Pharma
Target Validation
Target ID
Hit identif.
Hit to lead
Lead opt.
Preclin. Dev.
Clinical trials
Academy
Tech Transfer 1.0 The IFOM /IEO model
Academy Biotech/Pharma
PARTNERING AT LATER STAGE, A DE-‐RISKED MOLECULE
TTFACTOR
Our vision of Drug Discovery Process
TTFactor @ Laboratori dal Basso
• Self funded “industry-skilled” small molecule program;
• Science driven target identification and validation integrated with drug discovery efforts
• Targeting cancer’s “hottests targets”
• Major collaboration with MD Anderson Applied Cancer Institute in epigenetics
IEO Drug Discovery Program (DDP)
TTFactor @ Laboratori dal Basso
• a technology transfer company owned by IFOM and IEO
• exclusive licensee of all IEO’s and IFOM’s IP rights
• with exclusive right to nego>ate and sign contracts with THE FOR PROFIT SECTOR in name and on behalf of IFOM and IEO
• Exclusive consultants Centro Cardiologico Monzino
One step to decision and execuLon in all makers related to IP exploitaLon
TTFactor’s corporate backbone
TTFactor @ Laboratori dal Basso
Key “TT” FACTORs
• A Company facing Companies… A light structure allowing a >me effec>ve decision process and an efficient management of the nego>a>on • An interna>onal Board of Directors To take the advantage of years of succesful experience in technology transfer (improved learning curve) • Bring science to Market A strategic Business Development Advisory Board to help tailoring the market proposal for each project
TTFactor @ Laboratori dal Basso
Pier Giuseppe Pelicci, President -‐ IEO Claudio Basilico -‐ New York University Leonardo Biondi -‐ IFOM Mario Cesana -‐ IEO Andrea Cuomo -‐ ST Microelectronics Marco Foiani -‐ IFOM Isaac Kohlberg -‐ Harvard University Tomas Lindhal -‐ Cancer Research UK Elisabeaa Petrucci -‐ FIRC Domenico Triarico -‐ IEO
Daniela Bellomo, Managing director Marzia Fumagalli, Intellectual Property Jacopo Franchini, Business Development Giulia Negri, Marke3ng Barbara Gallone, Assistant
Team Board of Directors
Team and Board of Directors
Giulio Draeaa, MDACC Isaac Kohlberg, Harvard University Nagesh Mahantappa, CEO Scholar Rock Kazumi Shiosaki, MPM Capital Katherine Turner, Scholar Rock
Business Advisors
TTFactor @ Laboratori dal Basso
How do we operate?
abandon
more data needed abandon • Novelty search • Market search • Manageability
Feedback from Companies
Business Development Advisory Board
Develop Further (Internally or via Spin off)
License
Patent porsolio
In-‐licensing +
abandon
InvenLons
13
TTFactor @ Laboratori dal Basso
TTFactor Method of antigen loading for immunotherapy
I FOM-IEO-Campus, Mi lan, I ta ly
Last
up
da
te 0
2.2
01
1duction is in preparation for Phase I; the clinical trial in melanoma patients is planned for June-July 2011.
Applicabil ityNew method to generate potent DC-based
tumor vaccines
• Adjuvant treatment (to elimate mini-
mal residual disease) for the moment in
melanoma but it can be extended to other
diseases
• Metastatic melanoma
The European Institute of Oncology (IEO)
is available for clinical support, hosting
several studies on melanoma.
OpportunityWe are looking to partner this program for
further development with companies in
immuno-therapeutics and tumor vaccine.
ReferencesSaccheri F. et al. Bacteria-induced gap
junctions in tumors favor antigen cross-
presentation and antitumor immunity. Sci
Transl Med. 2010 Aug 11; 2(44): 44ra57.
Avogadri, F., et al.. Eur. J. Immunol. 2008
Jul;38(7):1937-47.
Patent ApplicationsUS 61/370,599
TTFactor (Sr l )V ia Adamel lo, 1620139 Mi lan ( I ta ly )
Germano Ferrari PhD, MBABusiness Development Manager
T +39 02 94375.140 E germano.ferrar [email protected] W www.ttfactor.com
IntroductionDendritic cells (DCs) are key players in the
activation of T cells. DCs are endowed
with the ability to present exogenous
antigens that have not been generated
within DCs for the activation of T cells, via
the cross-presentation pathway. Cross-
presentation is required for the initiation
of effective anti-tumor T cell responses
and the repertoire of presented peptides is
crucial to activate T cells that will recognize
and kill tumor cells. However, the antigen
presentation machinery, and in particular
the proteasome, differs between tumor
cells and DCs. A major drawback is that
DCs could process and present peptides
that are different from those presented by
tumor cells, thus initiating a tumor-specifi c
response that will not recognize the tumor.
Brief descriptionWe show that bacteria can be successfully
used to induce tumor to DC communica-
tion via gap-Junctions allowing cross-pre-
sentation of tumor antigens and effective
activation of tumor specifi c immune re-
sponses. Salmonella typhimurium infection
facilitates the cross-presentation of tumor
antigens and its exploitation can generate
potent DC-based tumor vaccines.
Thus, we have developed a new method of antigen cross presentation for immunotherapy, that has proven very effective in mice (see fi gure). Mice vaccinated with DCs loaded with bacteria-treated tumor cells are fully protected against challenge with the highly aggressive B16 melanoma. This mechanism has been confi rmed on hu-man cells in vitro and is under in vivo validation. The protocol for GMP pro-
2. Prior art & Market intelligence 5. Find partner and make the deal
1. IP culture & new inven>ons 3. Filed patent applica>on 4. Promote it and Publish
TTFactor @ Laboratori dal Basso
39
• Cash-‐in at sign (upfront) • Cash-‐in when reaching development goals (milestones)
• Cash-‐in once on the market (royal>es on sales)
MARKET -‐ PATIENTs Research Institution
Company
Right (development, marke3ng, distribu3on)
Upfront +
milestones
Royalties (% on sales)
A way to finance the Research Ins>tu>on and get the commitment from the developer (industrial partner)
• Cash-‐in at sign (upfront) • Cash-‐in when reaching development goals (milestones)
• Cash-‐in once on the market (royal>es on sales)
What does a licensing agreement mean?
TTFactor @ Laboratori dal Basso
PROJECT SOURCE IP DISCOVERY PRECLINIC CLINIC
PARTNERED
uPAR ANTAGONISTs & BIOMARKERs IFOM ✔
LDH INHIBITORS IEO ✔
mPTP INHIBITORS IEO/GNX ✔
HDAC INHIBITOR IEO/GNX ✔
miRNA DIAGNOSTIC TEST IFOM/IEO ✔
STEM CELL SIGNATURE IFOM/IEO
LSD-‐1 INHIBITORS IEO ✔
AVAILABLE FOR PARTNERING IN ONCOLOGY
RADIO-‐PHARMACEUTICALS ST/IEO ✔
NON CODING RNA (DDRNA) IFOM ✔
TARGET ID&VALIDATION IEO
scFv ANTIBODIES TARGETING TUMORs IEO
AVAILABLE FOR PARTNERING IN OTHER INDICATIONS
SHORT TSLP PEPTIDE IEO ✔
BACTERIAL/PROBIOTIC PLATFORM IEO ✔
BETA-‐CATENIN INHIBITORS IFOM ✔
GPR17 MODULATORS CCM ✔
iPS GENERATION FACTOR IFOM ✔
SMARTFOOD IEO
PATIENT DISEASE MODEL / DRUG SCREENING IEO
STROKE (HEARTH/BRAIN)
PARTNERED ONCOLOGY
PARTNERED CANCER Epigene>cS
IMMUNOTHERAPY
ONCOLOGY/AGEING
PARTNERED ONCOLOGY
PARTNERED DERMATOLOGY HEART DISEASE
PARTNERED LUNG CANCER
INFLAMMATION (IBD)
BRAIN RARE NGIOMA
✖
BREAST CANCER
IART-‐BREAST CANCER
NEGOTIATION
NUTRITION & SCIENCE
Biotech & VC
Biotech & VC PARTNERED
PARTNERED
AGGRESSIVE TUMORs
AGGRESSIVE TUMORs
REGEN. MEDICINE
AUTISM & WILLIAMS
A growing pipeline
TTFactor @ Laboratori dal Basso
• 104 invenLon disclosures from scien>sts 16 new patent families and 2 trademarks -‐ 7 in-‐licensed patent families
• 190 contracts with biotech/pharma/food companies, and selected Academic InsLtuLons
• 80 Non Disclosure Agreements including GSK, J&J Roche, Novar>s etc
• 9 license and/or co-‐development with European investment firms and companies
• a major alliance on drug discovery for epigene>c targets with MDACC
Food
Academia
Pharma & BIOTECH
In FOUR years
A solid track record
TTFactor @ Laboratori dal Basso
In TTFactor we aim not only to collect the but also to culLvate the tree. There are several models of Tech Transfer, more or less ac>ve towards the market depending on the features and voca>on of the model chosen. IFOM and IEO have invested in a innova>ve model of technology transfer in the Italian landscape:
A simple organiza>on, comparable on one hand to the industrial world and able, on the other one, to adapt itself to IEO and IFOM
strategies in R&D
Conclusion
TTFactor @ Laboratori dal Basso
VIDEO INTERVISTA SUL WORKSHOP TTFACTOR
Speakers:!• Gianmario Verona,
Vice Rector of Faculty, SDA Bocconi outgoing Director MBA!
• Federica Draghi, Business Development Director, Genextra!
• Rocco Paracchini, Senior Manager Global Sales, Aptalis Pharma!
• Olga Capasso, Patent Attorney, De Simone & Partners!
• Marzia Fumagalli, Intellectual Property Manager, TTFactor!
• Antonino Amato, Director Clinical Trial Center, Policlinico Gemelli!
• Marco Morello, Manager Healthcare & Life Science Division, PageGroup!
!!!Moderator:!• Daniela Bellomo,! Founder and Managing Director, TTFactor!
Agenda:!14.00 "Registration""14.30 "Round Table 1!"
"Careers in finance, investment, !corporate business development !"G.Verona, F.Draghi, R.Paracchini!
!!Recent experiences from your peers""E.Beltrami, J.Sgualdino, N.Bacchi!
!15.40 "Q&A""15.50 "Coffee Break!!16.15 !Round Table 2!
!!!Careers in intellectual property, !!tech transfer, regulatory & drug safety!!O.Capasso, M.Fumagalli, A.Amato!!!!A look at the Italian !healthcare job market and hints !on how to make a CV appealing !!M.Morello!
!17.20 !Q&A and meeting end"
Looking beyond the lab Workshop on career opportunities for qualified scientists
21 October 2014 Campus IFOM-IEO, Conference Room, Bldg. 9
IN COLLABORATION WITH: ORGANIZED BY:
Follow TTFactor on: #lookingbeyondthelab
TTFactor @ Laboratori dal Basso
Jacopo Franchini, MSc Business development & marketing Manager
• Prior joining TTFactor, Jacopo was Sales Area Manager for INDIA and MENA regions at Solmag-‐Olon, an API manufacturer.
• Previously he served as Contract Coordinator in the Business Development unit of MolMed S.p.A (MLM.MI), a Biotech Company focused on oncology.
• Internship at King’s College Business London Ltd, the tech transfer company of a major university in UK.
• Jacopo holds a Master degree in Pharmaceu>cal Biotechnology from Vita Salute San Raffaele University and he aaended different post graduate courses on patent management and business development: – MIP Corporate Master Program in Accoun>ng and Financial statements; – Intellectual Property and patents post graduate course at Universita’ di Pavia; – Business development course and licensing at Assobiotec Milano
TTFactor @ Laboratori dal Basso
Marzia Fumagalli, PhD, LLM Intellectual Property Manager
• Marzia Fumagalli joined TTFactor in 2011, after having collaborated with the Company since 2010.
• She holds an LLM (Master of Laws) in IP Law and Management (MIPLM) from CEIPI, Center for International Intellectual Property Studies, of University of Strasbourg.
• Prior joining to TTFactor, she was a postdoctoral research fellow in biomedical oncology at IFOM (The FIRC Institute of Molecular Oncology Foundation).
• Marzia obtained her PhD in Molecular Medicine from SEMM, the European School of Molecular Medicine, and she holds a Master Degree in Medical Biotechnology from University of Milan
TTFactor @ Laboratori dal Basso
CV • Founder and current Managing Director of TTFactor Srl (Milan) since 2010 • Director Technology Transfer Office at San Raffaele Hospital (Milan) 2002-‐2010 • Mater Business AadministraLon at University of Queensland Business School • Senior Officer at IMBcom (TTO -‐ University of Queensland) 2001-‐2002 • Post Doc at Queensland InsLtute for Medical Research (Australia) 1996-‐2000 • PhD student at St Georges’ Hospital Medical School (London, UK) 1992-‐1996 Other:. Member of the Board of Directors of the Parco Tecnologico Padano (www.technoparco.org), Italy’s largest scien>fic park dedicated to the agri-‐food sector by nominaLon by the Mayor of Milan
Daniela Bellomo, PhD, MBA Direttore Generale TTFactor
TTFactor @ Laboratori dal Basso
Daniela Bellomo, Managing director Marzia Fumagalli, Intellectual Property Jacopo Franchini, Business Development Giulia Negri, Marketing Barbara Gallone, Assistant
What I like the most of my job and which are the challenges…
Every day I learn something new both from science and from business
You need both an eye for details and an open mind
for the big picture
I enjoy working in a nimble ad streamlined
team with clear objectives
It is hard to estimate the value of an early technology still far
away from the market
It gives me a cross view of science
We have to keep everyone’s
expectations realistic
I love exploring the unknown and being part of
discoveries that will contribute to new
therapies
You work under pressure, managing many different tasks whilst respec3ng
deadlines
TTFactor @ Laboratori dal Basso
If you wish to learn more.. Tech Transfer: AUTM (hap://www.autm.net/) Associa>on of University Technology Managers ProTon (hap://www.protoneurope.org/) European Associa>on for Knowledge Transfer Netval (hap://www.netval.it/) Network for the valorisa>on of the University Italian research
Intellectual Property and Patents: EPO (hap://www.epo.org/) European Patent Office WIPO (hap://www.wipo.int/about-‐ip/en/iprm/) World Intellectual Property Organiza>on CEIPI (hap://www.ceipi.edu/) at Univ of Strasbourg Centre d'Etudes Interna>onales de la Propriete Intellectuelle
www.vactor.com
Follow us on @TTFactor